In addition, FGF21 resistance is observed in metabolic diseases including NAFLD [30], suggesting that aberrant expression in these scenarios may endow FGF21 with aberrant activities, such as the tumor-promoting effect observed in our study. The gene discussed is FGF21; the disease is metabolic dysfunction-associated steatotic liver disease.